Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype (Q39334333)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

15

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

John R. Mascola

13

object named as

John Mascola

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

David C. Montefiori

12

object named as

David Montefiori

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

Ranajit Pal

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

V S Kalyanaraman

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

B C Nair

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Stephen Whitney

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Timothy Keen

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Lindsey Hocker

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Lauren Hudacik

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Nicolas Rose

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Innocent Mboudjeka

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Siyuan Shen

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Te-Hui Wu-Chou

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Philip Markham

14

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

1 May 2006

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

348

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

341-353

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

2 references

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

based on heuristic

inferred from DOI database lookup

Cutaneous antigen priming via gene gun leads to skin-selective Th2 immune-inflammatory responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

DNA vaccines against human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Interactions of single and combined human immunodeficiency virus type 1 (HIV-1) DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Progress in the development of an HIV-1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Progress toward an HIV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Prospects for vaccine protection against HIV-1 infection and AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Vaccines for the prevention of HIV-1 disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Virological rebound after suppression on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Challenges and opportunities for development of an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

HIV-1 diversity and vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Immunopathogenesis of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Reduced immunogenicity of DNA vaccine plasmids in mixtures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

The moving target: mechanisms of HIV persistence during primary infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

Characterization of primary isolate-like variants of simian-human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

based on heuristic

inferred from DOI database lookup

Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2005.12.029

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2005.12.029

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39334333&oldid=1820601708"